University of Chicago Medicine Comprehensive Cancer Center | Strategic Alliance Partners

A focus on her passion for leukemia research and genuine care for her patients enabled Wendy Stock, MD, to rise above—one step at a time—as a mentor, leader, and pioneer.

Anand Patel, MD, shares primary efficacy results from a phase 2 study evaluating a TKI plus inotuzumab ozogamicin–based therapy in newly diagnosed Ph-positive ALL.

The top 5 OncLive TV videos of the week cover insights in breast cancer, uveal melanoma, prostate cancer, and multiple myeloma.

Wendy Stock, MD, discussed the role of molecular testing in Ph-positive ALL and best practices for implementing this testing across clinical scenarios.

Jessica Donington, MD, MSCR, discusses how updated data with perioperative nivolumab in NSCLC may affect future surgical decision-making.

In an OncLive Peer Exchange, expert investigators convened to discuss the treatment landscape of early-stage NSCLC from a multidisciplinary perspective.

Experts from across oncology specialties discuss the long-term effects of the COVID-19 pandemic on patient care.

Clinicians parse through the impacts of tumor-agnostic FDA approvals, examining T-DXd and repotrectinib's 2024 approvals in particular.

Michael R. Bishop, MD, discusses the potential significance of anitocabtagene autoleucel for the relapsed/refractory multiple myeloma treatment paradigm.

Michael R. Bishop, MD, discusses 34-month data from the iMMagine-1 trial of anitocabtagene autoleucel in relapsed/refractory myeloma.

S. Vincent Rajkumar, MD, of Mayo Clinic; Nosha Farhadfar, MD, of Methodist Physician Practices; and Sonali Smith, MD, of University of Chicago Medicine, sit down with Chandler Park, MD, FACP, to discuss the latest in multiple myeloma, graft-vs-host disease, and non-Hodgkin lymphoma, respectively, from the 2024 ASH Annual Meeting.

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on biomarker testing in metastatic or resectable non–small cell lung cancer.

An exploratory analysis from the TROPION-Lung 01 study shows that positivity for TROP2 normalized membrane ratio can be predictive for improved efficacy in patients with non–small cell lung cancer treated with datopotamab deruxtecan.

Sonali M. Smith, MD, discusses the current arsenal of bispecific antibodies available for the management of relapsed/refractory follicular lymphoma.

Rita Nanda, MD, discusses efforts to de-escalate adjuvant therapy for patients with select breast cancers who responded to neoadjuvant therapy.

John V. Heymach, MD, PhD, and Marina Chiara Garassino, MD, discuss data with perioperative durvalumab in resectable NSCLC in light of the ODAC decision.

The FDA has approved neoadjuvant durvalumab plus chemotherapy, followed by adjuvant durvalumab, for select resectable non–small cell lung cancer.

Drs Armstrong and Tawagi discuss the NADINA trial of neoadjuvant nivolumab/ipilimumab vs adjuvant nivolumab in resectable, macroscopic, stage III melanoma.

Chih-Yi Liao, MD, discusses treatment considerations for patients with hepatocellular carcinoma and emphasizes the need for a multidisciplinary approach.

Chih-Yi Liao, MD, discusses the treatment landscape of advanced biliary tract cancer and outlines therapy selection factors.

Dr Rosenberg discusses strategies for managing nasopharyngeal cancer and the role of toripalimab in this treatment paradigm.

In case you missed any, below is a recap of every OncLive On Air episode that aired in May 2024.

Thomas F. Gajewski, MD, PhD, discusses the mechanism through which the gut microbiome modulates myeloid cells to regulate responses to immunotherapy.

Ryan Merkow, MD, MS, and Louise Catherine Connell, MB BCh BAO, BMedSc, review cases of patients with colorectal cancer and provide insights on clinical practice.

Turning the focus of the conversation to clinical practice, experts on hepatic artery infusion therapy provide clinical insights on program development and evolution.

Drs Connell and Merkow discuss the current treatment landscape in intrahepatic cholangiocarcinoma and review recent clinical data in that space.

Louise Catherine Connell, MB BCh BAO, BMedSc, and Ryan Merkow, MD, MS, review clinical trial data on resected colorectal cancer liver metastases.

A surgical oncologist and gastrointestinal oncologist review data on hepatic artery infusion therapy in unresectable colorectal cancer liver metastases.

Two experts on gastrointestinal cancers give a broad overview of hepatic artery infusions.